Sublingual misoprostol vs oxytocin in women receiving prophylactic oxytocin
- January 16th, 2010
- Postpartum Hemorrhage
- Winikoff, Beverly, Diop, Ayisha, Blum, Jennifer, Dabash, Rasha, Raghavan, Sheila, Dzuba, Ilana, Durocher, Jill, Cherine Ramadan, M., Dilbaz, B., Dao, B., Yalvac, S., Ngoc, N.T.N
The Lancet; January 16, 2010; Vol. 375(9710):217-223; doi:https://doi.org/10.1016/S0140-6736(09)61923-1
This article describes the results of a clinical trial seeking to evaluate the use of misoprostol compared to standard oxytocics for treatment of postpartum hemorrhage in women receiving prophylactic oxytocin during labor. The results demonstrate that misoprostol is clinically equivalent to oxytocin when used to stop excessive post-partum bleeding suspected to be due to uterine atony under these circumstances.